Additional cancer-related mutations were identified and associated with ATRX alterations in 8 of 9 cases, TP53 mutations in 6 (3 aggressive corticotroph tumor, 2 corticotroph carcinomas, and 1 aggressive lactotroph tumor), PTEN mutations in 2, and RB1, NF2, and CDKN2A/B in single cases. Here, NF2 is linked to cancer.